Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease

Free Radical Research

Volumn 42, Issue 7, 2008, Pages 633-638

  Greilberger, Joachim ^a   Koidl, C ^a   Greilberger, M ^a   Lamprecht, M ^a   Schroecksnadel, K ^b   Leblhuber, F ^c   Fuchs, D ^b   Oettl, K ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Landes Nervenklinik ^*  (Austria)

Author keywords

Albumin disulphide (Alb SSR); Alzheimer's disease (AD); Carbonyl proteins (CP); Malondialdehyde (MDA); Mild cognitive impairment (MCI); Neuro degenerative diseases; Reactive oxygen and nitrogen species (RONS); Sulphydryl albumin (Alb SH)

Indexed keywords

ALBUMIN; BIOCHEMICAL MARKER; CARBONYL DERIVATIVE; CYANOCOBALAMIN; DISULFIDE; FOLIC ACID; HOMOCYSTEINE; LIPID; MALONALDEHYDE; NEOPTERIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COGNITIVE DEFECT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTHESIS; LIPID PEROXIDATION; MALE; NERVE DEGENERATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COGNITION DISORDERS; DISULFIDES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; NEOPTERIN; NERVE DEGENERATION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; VITAMIN B 12;

EID: 48449092905     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715760802255764     Document Type: Article

References (52)

1. Katzman, R. and Saitoh, T. (1991) Advances in Alzheimer's disease. 4, pp. 278-286.
2. Cecchi, C., Fiorillo, C., Sorbi, S., Latorraca, S., Nacmias, B., Bagnoli, S., Nassi, P. and Liguri, G. (2002) Oxidative stress and reduced antioxidant defences in peripheral cells from familial Alzheimer's patients. 33, pp. 1372-1379.
3. Perry, G., Nunomura, A., Hirai, K., Zhu, X., Perez, M., Avila, J., Castellani, RJ, Atwood, CS, Aliev, G., Sayre, LM, Takeda, A. and Smith, MA. (2002) Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. 33, pp. 1475-1479.
4. Smith, MA, Perry, G., Richey, PL, Sayre, LM, Anderson, VE, Beal, MF and Kowall, N. (1996) Oxidative damage in Alzheimer's. 382, pp. 120-121.
5. Boyd-Kimball, D., Castegna, A., Sultana, R., Fai Poon, H, Petroze, R., Lynn, BC, Klein, JB and Butterfield, DA. (2005) Proteomic identification of proteins oxidized by Aβ(1-42) in synaptosomes: Implications for Alzheimer's disease. 1044, pp. 206-215.
6. Liu, Q., Raina, AK, Smith, MA, Sayre, LM and Perry, G. (2003) Hydroxynonenal, toxic carbonyls, and Alzheimer disease. 24, pp. 305-313.
7. Picklo Sr, MJ, Montine, TJ, Amarnath, V. and Neely, MD. (2002) Carbonyl toxicology and Alzheimer's disease. 184, pp. 187-197.
8. Pratico, D., Clark, CM, Liun, F., Rokach, J., Lee, VY and Trojanowski, JQ. (2002) Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. 59, pp. 972-976.
9. Smith, CD, Carney, JM, Tatsumo, T., Tadtman, ER, Floyd, RA and Markesbery, WR. (1992) Protein oxidation in aging brain. 663, pp. 110-119.
10. Keller, JN, Schmitt, FA, Scheff, SW, Ding, Q., Chen, Q., Butterfield, DA and Markesbery, WR. (2005) Eividence of increased oxidative damage in subjects with mild cognitive impairment. 64, pp. 1152-1156.
11. Sayre, LM, Smith, MA and Perry, G. (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. 8, pp. 721-738.
12. Volicer, M. (1991) Free radicals in the development of Alzheimer's disease. 11, pp. 567-571.
13. Keller, JN. (2006) Interplay between oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease. 3, pp. 1-3.
14. Cecarini, V., Ding, Q. and Keller, JN. (2007) Oxidative inactivation of the proteasome in Alzheimer's disease. 41, pp. 673-680.
15. Pratico, D. and Sung, S. (2004) Lipid peroxidation and oxidative imbalance: Early functional event in Alzheimer's disease. 6, pp. 171-175.
16. Markesbery, WR and Lovell, MA. (2007) Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. 64, pp. 954-956.
17. Lovell, MA and Markesbery, WR. (2008) Oxidatively modified RNA in mild cognitive impairment. 28, pp. 169-175.
18. Ding, Q., Markesbery, WR, Cecarini, V. and Keller, JN. (2006) Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. 31, pp. 705-710.
19. Butterfiled, DA, Drake, J., Pocernich, C. and Castegna, A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. 7, pp. 548-554.
20. Choi, J., Malakowsky, CA, Talent, JM, Conrad, CC and Gracy, RW. (2002) Identification of oxidized plasma proteins in Alzheimer's disease. 293, pp. 1566-1570.
21. Conrad, CC, Marshall, PL, Talent, JM, Malakowsky, CA, Choi, J. and Gracy, RW. (2000) Oxidized proteins in Alzheimer's plasma. 275, pp. 678-681.
22. Beal, MF. (2002) Oxidatively modified proteins in aging and disease. 32, pp. 797-803.
23. Smith, MA, Harris, PLR, Sayre, LM, Beckham, JS and Perry, G. (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. 17, pp. 2653-2657.
24. Esterbauer, H., Schaur, J. and Zollner, H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde, and related aldehydes. 11, pp. 81-128.
25. Harman, D. (1995) Free radical theory of aging: Alzheimer's disease pathogenesis. 18, pp. 97-119.
26. Lovell, MA, Ehmann, WD, Butler, SM and Markesbery, WR. (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease and aging. 45, pp. 1594-1601.
27. Seidler, NW. and Yeargans, GS. (2004) Albumin-bound polyacrolein: implications for Alzheimer's disease. 320, pp. 213-217.
28. Himmelfarb, J. and McMonagle, E. (2001) Albumin is the major plasma protein target of oxidant stress in uremia. 60, pp. 358-363.
29. Ischiropoulos, H. and Beckman, JS. (2003) Oxidative stress and nitration in neurodegeneration: Cause, effect, or association?. 111, pp. 163-169.
30. McKhan, G., Drachman, D., Folstein, M., Katzman, R., Price, C. and Stardlan, M. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and human Services task force of Alzheimer's disease. 34, pp. 939-944.
31. Petersen, RC, Smith, GE, Waring, SC, Ivnik, RJ, Tangalos, EG and Kokmen, E. (1999) Mild cognitive impairment: Clinical characterization and outcome. 56, pp. 303-308.
32. Frick, B., Schrocksnadel, K., Neurauter, G., Wirletner, B., Artner-Dworzak, E. and Fuchs, D. (2003) Rapid measurement of total plasma homocysteine by HPLC. 331, pp. 19-23.
33. Khoschsorur, GA, Winklhofer-Roob, BM, Rabl, H., Auer, T., Peng, Z. and Schaur, RJ. (2000) Evaluation of a sensitive HPLC method for the determination of malondialdehyde, and application of the method to different biological materials. 52, pp. 181-184.
34. Hayashi, T., Era, S., Kawai, K., Imai, H., Nakamura, K., Onda, E. and Yoh, M. (2000) Observation for redox state of human serum and aqueous human albumin from patients with senile cataract 6, pp. 237-243.
35. Lamprecht, M., Greilberger, J. and Oettl, K. (2004) Analytical aspects of oxidatively modified substances in sports and exercises. 20, pp. 728-730.
36. Ahlskog, JE, Uitti, RJ, Low, PA, Tyce, GM, Nickander, KK, Petersen, R. and Kokmen, E. (1995) No evidence for systemic oxidative stress in Parkinson's or Alzheimer's disease. 10, pp. 566-573.
37. Kalman, J., Kudchodkar, BJ, Murray, K., McConathy, WJ, Juhasz, A., Janka, Z. and Lacko, AG. (1999) Evaluation of serum-lipid-related cardiovascular risk factors in Alzheimer's disease. 10, pp. 488-493.
38. Smith, MA, Harris, PLR, Sayre, LM and Perry, G. (1997) Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. 94, pp. 9866-9868.
39. Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, SP, Wu, JF, Carney, JM, Lovell, M., Markesbery, WR and Butterfield, DA. (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. 5, pp. 2146-2156.
40. McGrath, LT, McGleenon, BM, Brennan, S., McColl, D., McILroy, S. and Passmore, AP. (2001) Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. 94, pp. 485-490.
41. Bermejo, P., Martin-Aragon, S., Benedi, J., Susin, C., Felici, E., Gil, P., Ribera, JM and Villar, AM. (2008) Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from mild cognitive impairment. 42, pp. 162-170.
42. Mattson, MP, Guo, Q., Furukawa, K. and Pedersen, WA. (1998) Presenilins, the endoplasmatic reticulum and neuronal apoptosis in Alzheimer's disease. 70, pp. 1-14.
43. Era, S., Kuwata, K., Imai, H., Nakamura, K., Hayashi, T. and Sogami, M. (1995) Age-related change in redox state of human serum albumin. 1247, pp. 12-16.
44. Soejima, A., Matsuzawa, N., Hayashi, T., Kimura, R., Ootsuka, T., Fukuoka, K., Yamada, A., Nagesawa, T. and Era, S. (2004) Alteration of redox state of human serum albumin before and after hemodialysis. 22, pp. 525-529.
45. Suzuki, E., Yasuda, K., Takeda, N., Sakata, S., Era, S., Kuwata, K., Sogami, M. and Miura, K. (1992) Increased oxidized form of human serum albumin in patients with diabetes mellitus. 18, pp. 153-158.
46. Lehmann, M. (1999) Identification of cognitive impairment in the elderly: Homocysteine is an early marker. 10, pp. 12-20.
47. McCaddon, A. (1998) Total serum homocysteine in senile dementia of Alzheimer type. 13, pp. 235-239.
48. Kado, DM, Karlamangala, AS, Huang, MH, Troen, A., Rowe, JW, Selhub, J. and Seeman, TE. (2005) Homocysteine versus the vitamins folate, B6 and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of successful aging. 118, pp. 161-167.
49. Kalmijn, S., Launer, LJ, Lindemans, J., Bots, ML, Hofman, A. and Breteler, MM. (1999) Total homocysteine and cognitive decline in a community-based sample of elderly subjects: The Rotterdam Study. 150, pp. 283-289.
50. Ravaglia, G., Forti, P., Maioli, F., Vettori, C., Grossi, G., Bargossi, AM, Caldarera, M., Franzeschi, C., Facchini, A., Mariani, E. and Cavalli, G. (2000) Elevated plasma homocysteine levels in centarians are not associated with cognitive impairment. 121, pp. 251-261.
51. Mizrahi, EH, Bowirrat, A., Jacobsen, DW, Korczyn, AD, Traore, F., Petot, AJ, Lerner, AJ, Debanne, SM, Adunsky, PM, DiBello, PM and Friedland, RP. (2004) Plasma homocysteine, vitamin B12 and folate in Alzheimer's patients and healthy Arabs in Israel. 227, pp. 109-113.
52. McGrath, LT, McGleenon, BM, Brennan, S., McColl, D., McIlroy, S. and Passmore, AP. (2001) Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. 94, pp. 485-490.